Company Overview

Company name: Zelira Therapeutics (ASX: ZLD)
Description: Zelira Therapeutics Ltd is an Australia-based biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in a breast, brain, and pancreatic cancer. Geographically, it derives a majority of revenue from Australia.
Year founded: 2015
Parent company:
Industry: Healthcare | Group: | Code:
Employees: 8
City: Perth
State: Western Australia
Country: Australia

Financial Highlights

Start up capital raised (USD Million): 14.74
Business status: Generating Revenue
Ownership: Publicly Held
Exchange: ASX
Ticker: ZLD
Revenue (USD Million):
Gross profit (USD Million):
Net income (USD Million)
Enterprise value: 35.12
Earnings before interest, tax, depreciation and amortization (EBITDA):
Fiscal period: FY 2020
Financing Status:
Number of active investors:
Profile last updated: 03-Sep-2020
Last known valuation:
Last known valuation date: